Resolvin D2 prevents inflammation and oxidative stress in the retina of streptozocin-induced diabetic mice.
Resolvin D2
diabetes
inflammation
oxidative stress
retina
Journal
International journal of clinical and experimental pathology
ISSN: 1936-2625
Titre abrégé: Int J Clin Exp Pathol
Pays: United States
ID NLM: 101480565
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
05
2020
accepted:
29
06
2020
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
Diabetic retinopathy is the main ocular complication of diabetes mellitus. The aim of this study was to investigate the protective effect and mechanism of resolvin D2 (RvD2) on diabetic retinopathy. Streptozocin-induced C57/BJ diabetic mice were divided into three groups: normal control, diabetes mellitus, and diabetes plus RvD2 treatment. After three months of diabetic model induction, exogenous RvD2 was injected, monthly for three months, into the vitreous cavity of mice in the diabetic treatment group. Retinal vascular leakage, ganglion cell apoptosis, inflammatory factor expression, and oxidative stress factors were detected one month after the last injection. The levels of retinal vascular leakage and ganglion cell apoptosis in diabetic mice treated with RvD2 were significantly lower than those in untreated diabetic mice, as were the retinal levels of inflammatory factors and oxidative stress. In conclusion, RvD2 might be used as a retinal protective factor for diabetes mellitus by reducing inflammation and oxidative stress.
Types de publication
Journal Article
Langues
eng
Pagination
1986-1994Informations de copyright
IJCEP Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Int J Mol Sci. 2019 Sep 07;20(18):
pubmed: 31500240
Eye (Lond). 2017 Aug;31(8):1122-1130
pubmed: 28452994
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2706-13
pubmed: 27191823
Diabetologia. 2019 Sep;62(9):1539-1549
pubmed: 31346658
Nutrients. 2017 Oct 24;9(10):
pubmed: 29064407
J Immunol. 2017 Jan 15;198(2):842-851
pubmed: 27994074
Front Immunol. 2018 Apr 25;9:785
pubmed: 29922275
Diabet Med. 2013 Jun;30(6):640-50
pubmed: 23205608
JAMA Ophthalmol. 2017 Jun 1;135(6):558-568
pubmed: 28448655
Curr Diab Rep. 2017 Aug 24;17(10):93
pubmed: 28836097
Front Immunol. 2019 Feb 26;10:307
pubmed: 30863409
Semin Immunopathol. 2019 Jul;41(4):427-445
pubmed: 31175392
J Diabetes Res. 2019 Aug 14;2019:5140521
pubmed: 31485452
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2369-2379
pubmed: 31141608
Ophthalmology. 2016 Jun;123(6):1351-9
pubmed: 26935357
J Clin Med. 2019 Jul 14;8(7):
pubmed: 31337130
Drug Discov Today. 2019 Dec;24(12):2247-2257
pubmed: 31430543
J Burn Care Res. 2018 Apr 20;39(3):423-432
pubmed: 28877131
Exp Eye Res. 2004 Aug;79(2):275-85
pubmed: 15325574
Circulation. 2016 Aug 30;134(9):666-680
pubmed: 27507404
Mol Brain. 2018 Feb 13;11(1):9
pubmed: 29439730
Curr Diab Rep. 2019 Jul 29;19(9):67
pubmed: 31359159
J Diabetes Res. 2019 Aug 14;2019:8562408
pubmed: 31511825
Invest Ophthalmol Vis Sci. 2001 Mar;42(3):789-94
pubmed: 11222542
Neurochem Res. 2018 Dec;43(12):2384-2392
pubmed: 30443715